Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BMRA 
Biomerica Inc (BMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: BMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.4% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.50M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 31345 | Beta 0.33 | 52 Weeks Range 1.93 - 8.80 | Updated Date 06/17/2025 |
52 Weeks Range 1.93 - 8.80 | Updated Date 06/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -85.42% | Operating Margin (TTM) -108.13% |
Management Effectiveness
Return on Assets (TTM) -35.99% | Return on Equity (TTM) -72.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5987845 | Price to Sales(TTM) 1.5 |
Enterprise Value 5987845 | Price to Sales(TTM) 1.5 | ||
Enterprise Value to Revenue 1.05 | Enterprise Value to EBITDA -5.42 | Shares Outstanding 2545760 | Shares Floating 2384045 |
Shares Outstanding 2545760 | Shares Floating 2384045 | ||
Percent Insiders 10.13 | Percent Institutions 5.8 |
Analyst Ratings
Rating - | Target Price 13 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biomerica Inc
Company Overview
History and Background
Biomerica Inc. was founded in 1971. It is a global biomedical technology company that develops, manufactures, and commercializes diagnostic and therapeutic products for gastrointestinal and other disorders. It has evolved from a research and development company to a commercial entity with a focus on proprietary and patented technologies.
Core Business Areas
- Diagnostics: Develops and commercializes diagnostic test kits used in the early detection and diagnosis of various gastrointestinal and other diseases.
- Therapeutics: Develops and commercializes therapeutic products targeting gastrointestinal disorders and other diseases.
- Medical Devices: Develops and commercializes point-of-care diagnostics.
Leadership and Structure
Zackary Irani is the Chairman, President, and CEO. The company has a typical corporate structure with departments including Research and Development, Manufacturing, Sales and Marketing, and Finance.
Top Products and Market Share
Key Offerings
- InFoods IBS Diagnostic: Diagnostic test for Irritable Bowel Syndrome (IBS). Market share is not publicly available. Competitors include Commonwealth Diagnostics International, Genova Diagnostics, and other GI diagnostic companies. Revenue from the IBS test is estimated to be significant but undisclosed.
- EZ Detect Colorectal Disease Screening Test: Fecal occult blood test for colorectal disease screening. Market share is relatively small compared to larger players in the FOBT market, such as Exact Sciences (COL). Competitors include Polymedco and Beckman Coulter.
- HpDetect Helicobacter Pylori Test: Rapid immunoassay to detect H. pylori infection, a leading cause of stomach ulcers and gastric cancer. Competitors include Thermo Fisher Scientific and QuidelOrtho Corporation.
Market Dynamics
Industry Overview
The biomedical technology industry is characterized by innovation, regulatory scrutiny, and competitive pressures. Demand for diagnostics and therapeutics is driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
Biomerica is positioned as a niche player focusing on gastrointestinal disorders and related diagnostics. Its competitive advantage lies in its proprietary technologies and patented products, particularly in the IBS diagnostic space. It has a smaller marketing and distribution infrastructure compared to larger competitors.
Total Addressable Market (TAM)
The total addressable market for gastrointestinal diagnostics and therapeutics is estimated to be in the billions of dollars globally. Biomerica's positioning targets specific segments within this TAM, focusing on underserved areas like IBS diagnostics.
Upturn SWOT Analysis
Strengths
- Proprietary and patented technologies
- Focus on specialized niche markets (GI disorders)
- Established distribution network
- Experience in regulatory approvals
Weaknesses
- Limited financial resources compared to larger competitors
- Smaller sales and marketing infrastructure
- Dependence on a limited number of key products
- Potential for reimbursement challenges for novel diagnostics
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic and therapeutic products
- Partnerships with larger pharmaceutical companies
- Increased awareness and adoption of personalized medicine
Threats
- Competition from larger, more established companies
- Changes in reimbursement policies
- Regulatory hurdles for new products
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Exact Sciences (EXAS)
- Thermo Fisher Scientific (TMO)
- QuidelOrtho Corporation (QDEL)
Competitive Landscape
Biomerica faces intense competition from larger, more established companies. Its advantages include its proprietary technologies and niche focus, but it is disadvantaged by its limited resources and smaller market presence.
Major Acquisitions
Awareness Technology, Inc.
- Year: 2006
- Acquisition Price (USD millions): 5.8
- Strategic Rationale: Acquisition of the clinical chemistry analyzer business to further diversify Biomerica's product offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, driven by sales of existing products and new product launches. Growth rates have varied depending on market conditions and regulatory approvals.
Future Projections: Future growth projections are dependent on the successful commercialization of new products and expansion into new markets. Analyst estimates are not readily available. The future growth is highly dependent on the success of InFoods IBS Diagnostic test.
Recent Initiatives: Recent initiatives include expanding the commercial reach of the InFoods IBS Diagnostic, pursuing regulatory approvals in new markets, and investing in research and development for new products.
Summary
Biomerica is a niche player in the biomedical technology industry with proprietary diagnostic and therapeutic products, particularly in the gastrointestinal space. While its specialized focus and patented technologies are strengths, its limited resources and competition from larger firms present challenges. Successful commercialization of new products, particularly the IBS diagnostic, and expansion into new markets are crucial for future growth. The company needs to carefully manage regulatory hurdles and reimbursement challenges to maintain its competitive position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomerica Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2005-01-03 | CEO & Director Mr. Zackary S. Irani | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.biomerica.com |
Full time employees 64 | Website https://www.biomerica.com | ||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.